The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.
Bio-Rad Laboratories, Inc. Class B (BIO.B)
Common Stock · Currency in USD · XNYS
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Company Info
SIC3826
Composite FIGIBBG000BD6WM7
CIK0000012208
IPODec 30, 1899
Sectorlaboratory analytical instruments
Highlights
Market Cap$7.51B
EPS$46.68
P/E Ratio5.91
Revenue$2.47B
Gross Profit$1.38B
Net Income$1.27B
Employees7,450
WSO26,990,394
Phone(510) 724-7000
Websitehttps://www.bio-rad.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Bio-Rad Laboratories, Inc. Class B, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Bio-Rad Laboratories, Inc. Class B (BIO.B) has returned -11.03% so far this year and 23.51% over the past 12 months. Looking at the last ten years, BIO.B has achieved an annualized return of 7.20%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
BIO.B
1M3.90%
6M-13.35%
YTD-11.03%
1Y23.51%
5Y-14.27%
10Y7.20%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Bio-Rad Laboratories, Inc. Class B (BIO.B) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.71% | -1.31% | ||||||||||
| 2025 | 4.88% | -9.25% | -8.96% | 4.05% | -4.15% | 0.36% | -5.60% | 1.61% | ||||
| 2024 | 0.47% | 0.93% | 0.67% | -14.40% | -1.95% | -2.05% | -3.40% | |||||
| 2023 | -20.10% | -4.85% | -13.95% | 2.26% | 3.57% | |||||||
| 2022 | -17.22% | 5.21% | -4.61% | -12.80% | -14.75% | 0.01% | -6.50% | -10.36% | -20.51% | -5.23% | ||
| 2021 | -8.11% | 7.93% | -0.41% | 5.16% | 0.98% | 10.42% | 6.12% | 0.20% | -6.32% | -1.10% | -2.93% | |
| 2020 | 1.23% | -5.41% | 8.41% | 26.34% | 4.43% | -2.90% | 4.54% | -1.31% | 0.55% | 11.00% | -9.92% | 3.20% |
| 2019 | 5.28% | 9.07% | -5.16% | 6.34% | 2.86% | 9.66% | 0.24% | 7.38% | 1.08% | 7.76% | ||
| 2018 | 2.43% | 0.65% | -5.48% | 4.72% | 14.05% | -3.45% | 1.07% | 4.24% | -8.20% | 0.37% | 2.46% | -17.03% |
| 2017 | -0.31% | 1.30% | -0.60% | -1.19% | 0.45% | 1.97% | 3.75% | -8.85% | 5.61% | 0.45% | 9.94% | -6.66% |
| 2016 | 1.74% | 3.87% | -4.66% | 1.13% | 6.59% | 7.89% | 0.59% | 3.77% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Bio-Rad Laboratories, Inc. Class B (BIO.B) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of BIOB compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Bio-Rad Laboratories, Inc. Class B volatility is 6.27%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 10.58B | 12.30B | 13.50B | 17.78B | 12.97B | 8.01B | 5.61B | 4.27B | 3.71B | 3.34B | 3.39B | 3.44B | 3.10B |
| Equity Attributable To Parent (USD) | 7.45B | 8.74B | 9.62B | 13.67B | 9.88B | 5.76B | 4.02B | 2.93B | 2.49B | 2.19B | 2.19B | 2.01B | 1.74B |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | 535.00K | 445.00K |
| Equity (USD) | 7.45B | 8.74B | 9.62B | 13.67B | 9.88B | 5.76B | 4.02B | 2.93B | 2.49B | 2.19B | 2.19B | 2.01B | 1.74B |
| Other Non-current Liabilities (USD) | 1.40B | 1.83B | - | - | - | - | - | - | - | - | 278.80M | 222.96M | 161.01M |
| Long-term Debt (USD) | 1.20B | 1.21B | - | - | - | - | - | - | - | - | 435.80M | 732.60M | 732.30M |
| Noncurrent Liabilities (USD) | 2.61B | 3.04B | 3.32B | 3.43B | 2.46B | 1.35B | 1.14B | 840.07M | 779.69M | 709.36M | 714.60M | 955.56M | 893.31M |
| Other Current Liabilities (USD) | 215.70M | 238.25M | 238.88M | 262.01M | 269.21M | 618.40M | 184.84M | 195.88M | 161.10M | 164.73M | 208.30M | 203.10M | 217.43M |
| Wages (USD) | 172.30M | 139.93M | 194.79M | 276.99M | 222.88M | 180.08M | 143.51M | 171.63M | 157.86M | 153.43M | 130.66M | 135.96M | 112.56M |
| Accounts Payable (USD) | 129.00M | 144.63M | 135.04M | 141.94M | 139.45M | 107.01M | 122.45M | 135.18M | 122.39M | 128.61M | 148.51M | 130.87M | 129.12M |
| Current Liabilities (USD) | 517.00M | 522.80M | 568.71M | 680.94M | 631.54M | 905.50M | 450.80M | 502.70M | 441.35M | 446.76M | 487.47M | 469.92M | 459.12M |
| Liabilities (USD) | 3.12B | 3.56B | 3.89B | 4.11B | 3.09B | 2.25B | 1.59B | 1.34B | 1.22B | 1.16B | 1.20B | 1.43B | 1.35B |
| Other Non-current Assets (USD) | 6.96B | 8.40B | 9.51B | 15.04B | 10.14B | 5.18B | 2.95B | 1.63B | 1.28B | 941.85M | 1.21B | 1.09B | 949.15M |
| Intangible Assets (USD) | 174.30M | 320.51M | 332.15M | 253.94M | 199.50M | 145.53M | 133.12M | 174.11M | 214.03M | 254.23M | - | - | - |
| Fixed Assets (USD) | 539.90M | 529.01M | 498.61M | 490.95M | 491.37M | 499.34M | 508.69M | 493.50M | 437.69M | 428.84M | 429.36M | 416.94M | 349.50M |
| Noncurrent Assets (USD) | 7.67B | 9.25B | 10.34B | 15.79B | 10.83B | 5.83B | 3.59B | 2.30B | 1.93B | 1.62B | 1.64B | 1.51B | 1.30B |
| Other Current Assets (USD) | 2.03B | 2.13B | 2.31B | 1.31B | 1.43B | 1.52B | 1.25B | 1.24B | 1.19B | 1.14B | 1.11B | 1.48B | 1.36B |
| Prepaid Expenses (USD) | 136.50M | 140.04M | 124.18M | 107.75M | 90.62M | 102.33M | 187.25M | 146.14M | 94.37M | 108.35M | 135.97M | - | - |
| Inventory (USD) | 740.70M | 780.52M | 719.32M | 572.24M | 622.25M | 554.01M | 583.82M | 594.80M | 490.22M | 471.00M | 501.29M | 448.37M | 433.51M |
| Current Assets (USD) | 2.91B | 3.05B | 3.16B | 1.99B | 2.14B | 2.18B | 2.02B | 1.98B | 1.78B | 1.72B | 1.75B | 1.93B | 1.80B |
| Assets (USD) | 10.58B | 12.30B | 13.50B | 17.78B | 12.97B | 8.01B | 5.61B | 4.27B | 3.71B | 3.34B | 3.39B | 3.44B | 3.10B |
News and Insights
The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.
The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.
The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.
The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.
The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.
The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest product category. Key industry players are advancing NGS technology through strategic partnerships and innovative platforms.
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).
The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.
The global custom antibody market is projected to grow from USD 608.75 million in 2025 to USD 1,297.65 million by 2033, at a CAGR of 9.98%. Growth is driven by increasing demand for precision medicine, targeted therapies, advancements in antibody engineering, and rising investments in biopharmaceutical R&D. However, high development costs and technical challenges may hinder market expansion.